Search Results - "Cesas, Alvydas"

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) by Pinter, Tamás, Klippel, Zandra, Cesas, Alvydas, Croitoru, Adina, Decaestecker, Jochen, Gibbs, Peter, Hotko, Yevhen, Jassem, Jacek, Kurteva, Galina, Novotny, Jan, O'Reilly, Seamus, Salek, Tomas, Reiner, Maureen, Morrow, Phuong Khanh, Choi, Mi Rim, Whittaker, Sadie, Blanke, Charles

“…In a phase III, double-blind trial, 845 patients with advanced colorectal cancer receiving bevacizumab plus first-line chemotherapy (FOLFOX [leucovorin),…”
Get full text

Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer: a consensus of Lithuanian medical oncologists, radiation oncologists, endocrinologists, and family medicine physicians by Juozaitytė, Elona, Aleknavičius, Eduardas, Jančiauskienė, Rasa, Cesas, Alvydas, Pipirienė-Želvienė, Teresė, Liutkauskienė, Sigita, Krasauskienė, Aurelija, Vencevičienė, Lina

“…The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted…”
Get full text

Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel by Steger, Guenther G., Abrahámová, Jitka, Bacanu, Florin, Brincat, Stephen, Brize, Arija, Česas, Alvydas, Čufer, Tanja, Dank, Magdolna, Duchnowska, Renata, Eniu, Alexandru, Jassem, Jacek, Kahán, Zsuzsanna, Matos, Erika, Padrik, Peeter, Plāte, Signe, Pokker, Helis, Purkalne, Gunta, Timcheva, Constanta, Tzekova, Valentina, Vyzula, Rostislav, Zielinski, Christoph C.

“…Summary In breast cancer, early detection as well as new developments in therapeutic options has resulted in less patients presenting with metastatic disease…”
Get full text

Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions by Pikturniene, Rugile, Cesas, Alvydas, Jarmalaite, Sonata, Razbadauskas, Arturas, Urbonas, Vincas

“…Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint…”
Get full text

Sequential treatment of metastatic renal cell carcinoma patients after first-line vascular endothelial growth factor targeted therapy in a real-world setting: epidemiologic, noninterventional, retrospective–prospective cohort multicentre study by Cesas, Alvydas, Urbonas, Vincas, Tulyte, Skaiste, Janciauskiene, Rasa, Liutkauskiene, Sigita, Grabauskyte, Ingrida, Gaidamavicius, Ignas

“…Purpose The purpose of our study was to determine whether data on the clinical effectiveness of second-line therapy collected in a real-world setting provide…”
Get full text

Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II) by Atkinson, Victoria, Sandhu, Shahneen, Hospers, Geke, Long, Georgina V., Aglietta, Massimo, Ferrucci, Pier F., Tulyte, Skaiste, Cappellini, Gian Carlo Antonini, Soriano, Virtudes, Ali, Sayed, Poprach, Alexandr, Cesas, Alvydas, Rodriguez-Abreu, Delvys, Lau, Mike, de Jong, Egbert, Legenne, Philippe, Stein, Dara, King, Brianna, van Thienen, Johannes V.

“…In clinical trials, dabrafenib plus trametinib improved overall survival (OS) compared with single-agent BRAF inhibitors (BRAFi) in patients with BRAF…”
Get full text

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial by Vogelzang, Nicholas J, Beer, Tomasz M, Gerritsen, Winald, Oudard, Stéphane, Wiechno, Pawel, Kukielka-Budny, Bozena, Samal, Vladimir, Hajek, Jaroslav, Feyerabend, Susan, Khoo, Vincent, Stenzl, Arnulf, Csöszi, Tibor, Filipovic, Zoran, Goncalves, Frederico, Prokhorov, Alexander, Cheung, Eric, Hussain, Arif, Sousa, Nuno, Bahl, Amit, Hussain, Syed, Fricke, Harald, Kadlecova, Pavla, Scheiner, Tomas, Korolkiewicz, Roman P, Bartunkova, Jirina, Spisek, Radek

“…DCVAC/PCa is an active cellular immunotherapy designed to initiate an immune response against prostate cancer. To evaluate the efficacy and safety of DCVAC/PCa…”
Get more information

European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatment by Derksen, Jeroen W.G., Warren, Graham W., Jordan, Karin, Rauh, Stefan, Vera García, Ruth, O'Mahony, Deirdre, Ahmed, Samreen, Vuylsteke, Peter, Radulovic, Sinisa, Tsoukalas, Nikolaos, Wysocki, Piotr J., Borner, Markus, Cesas, Alvydas, Elme, Anneli, Minn, Heikki, Ullenhag, Gustav J., Roodhart, Jeanine M.L., Koopman, Miriam, May, Anne M.

“…Smoking cessation after a cancer diagnosis is associated with improved overall survival. Few studies have reported oncologists' cessation practice patterns,…”
Get full text

Guidelines for diagnostics and treatment of aromatase inhibitor-induced bone loss in women with breast cancer by Juozaitytė, Elona, Aleknavičius, Eduardas, Jančiauskienė, Rasa, Česas, Alvydas, Pipirienė-Želvienė, Teresė, Liutkauskienė, Sigita, Krasauskienė, Aurelija, Vencevičienė, Lina

“…The aim of this article is to inform about cancer treatment-induced bone loss, to identify patients at risk and those that can benefit from bone targeted…”
Get full text

P-675 Anemia in lung cancer patients and correction with EPREX (erithropoethinum alpha) by Cesas, Alvydas

Get full text

RAINBOW: A global, phase 3, double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo (PL) plus PTX in the treatment of advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line platinum- and fluoropyrimidine-containing combination therapy—An age-group analysis by Muro, Kei, Bodoky, Gyorgy, Cesas, Alvydas, Chao, Yee, Clingan, Philip, Hironaka, Shuichi, Komatsu, Yoshito, Kurteva, Galina Petrova, Lipatov, Oleg N., Nishina, Tomohiro, Oh, Sang Cheul, Ohtsu, Atsushi, Shimada, Yasuhiro, Sugimoto, Naotoshi, Van Cutsem, Eric, Carlesi, Roberto, Chandrawansa, Kumari, Wilke, Hansjochen

“…Abstract only 11 Background: RAM is a human IgG 1 monoclonal antibody VEGF-R2 antagonist. The RAINBOW trial demonstrated that RAM added to PTX significantly…”
Get full text

Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC) by Pinter, Tamas, Abella, Esteban, Cesas, Alvydas, Croitoru, Adina, Decaestecker, Jochen, Gibbs, Peter, Hotko, Yevhen, Jassem, Jacek, Kurteva, Galina Petrova, Novotny, Jan, O'Reilly, Seamus, Salek, Tomas, Mo, May F., Choi, L. Mi Rim, Blanke, Charles Davic

“…Abstract only 3575 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant…”
Get full text

Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC) by Pinter, Tamas, Abella, Steve, Cesas, Alvydas, Croitoru, Adina, Decaestecker, Jochen, Gibbs, Peter, Hotko, Yevhen, Jassem, Jacek, Kurteva, Galina Petrova, Novotny, Jan, O'Reilly, Seamus, Salek, Tomas, Mo, May F., Choi, L. Mi Rim, Blanke, Charles Davic

“…Abstract only LBA445 Background: The literature reports that adding biologics to chemotherapy (ctx) may increase the incidence of clinically significant…”
Get full text

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the PAVES Study by Pinter, Tamás, Klippel, Zandra, Cesas, Alvydas, Croitoru, Adina, Decaestecker, Jochen, Gibbs, Peter, Hotko, Yevhen, Jassem, Jacek, Kurteva, Galina, Novotny, Jan, O’Reilly, Seamus, Salek, Tomas, Reiner, Maureen, Morrow, Phuong Khanh, Choi, Mi Rim, Whittaker, Sadie, Blanke, Charles

“…Abstract Background Pegfilgrastim’s role in reducing febrile neutropenia (FN) risk in patients with colorectal cancer (CRC) receiving chemotherapy plus…”
Get full text

Combined treatment of esophageal cancer: a review by Cesas, Alvydas, Bagajevas, Aleksandras

“…While still relatively uncommon in many countries, esophageal cancer is fatal in the vast majority of cases. In the USA, estimated 13,100 of new cases were…”
Get more information